Assessing the safety and efficacy of biotherapeutics is imperative during the drug-development process. In particular, pharmacokinetic (PK) and anti-drug antibody (ADA) assays are conducted to study and evaluate new drug candidates and biosimilars. For PK/ADA assays, anti-idiotype antibodies (Anti-IDs) are powerful tools to measure the concentration of antibody drugs in patient samples and serve as […]

- Home
- News
- DDW Exclusive Content
- Opinion
- Business
- Regulatory
- Intelligence
Categories
Latest Industry Intelligence
- Cancer Research
- Webinars
- Podcasts
- Archive
- Videos